Torrent Pharma recalls bottles of Telmisartan, Hydrochlorothiazide tablets in US
According to the US health regulator, the drug maker is recalling the affected lot due to it being "Superpotent; Hydrochlorothiazide."
Advertisement
New Delhi: Torrent Pharma is recalling more than 27,000 bottles of its generic drug, used in lowering high blood pressure, in the US market. As per the latest enforcement report by the US Food and Drug Administration (USFDA), the Ahmedabad-based company is recalling 27,312 bottles of the Telmisartan and Hydrochlorothiazide tablets.
The affected lot has been produced in India and later the company has supplied to its US-based subsidiary for distribution in the US, the world's largest market for generic drugs.
According to the US health regulator, the drug maker is recalling the affected lot due to it being "Superpotent; Hydrochlorothiazide."
"New Jersey-based Torrent Pharma Inc, a unit of the company, has initiated the Class III nationwide (US) recall of the 40 mg/12.5 mg, 30 count bottles on December 1, this year," reports PTI.
Telmisartan Hydrochlorothiazide comprises two medicines, both of which help to control high blood pressure.
It is generally used when one medicine alone is not controlling the blood pressure effectively.
Lowering blood pressure helps to reduce your risk of having a heart attack or a stroke.
As per USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."
The US generic drug market was estimated to be around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products.
Read also: Lupin recalls cartons of oral contraceptive drug Tydemy in US
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC).
Read also: Torrent pharma successfully completes USFDA inspection for Levittown facility
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.